RVL Pharmaceuticals plc Income (Loss) from Continuing Operations, Per Basic and Diluted Share
RVL Pharmaceuticals plc reported Income (Loss) from Continuing Operations, Per Basic and Diluted Share of -$1.47 per share for the 12-month period ending 2020-12-31, per its 8-K filed 2021-09-08.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare · last filed 2021-09-08
| Period end | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 12 month |
|---|---|
| 2020-12-31 | -$1.47 8-K · filed 2021-09-08 |
| 2019-12-31 | -$2.43 8-K · filed 2021-09-08 |